drugset / Trial / NCT00837265
Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel
RandomizedParallel-groupOpen-labelSupportive care
Summary
Determination of the effect of balugrastim on the duration and severity of severe neutropenia.
Timeline
- Start
- 2008-08-21
- Primary completion
- 2009-06-26
- Completion
- 2009-06-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Balugrastim | Protein / enzyme biologic | — | Subcutaneous |
| Comparator | Pegfilgrastim | Protein / enzyme biologic | 6 mg | Subcutaneous |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Background | Doxorubicin | Other / unclassified | 60 mg/m2 | Intravenous |